3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
34
Prostatic Neoplasms, Castration-Resistant
3
Metastatic Castration-resistant Prostate Cancer
2
Metastatic Castration-Resistant Prostate Cancer
2
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Prostate Cancer Metastatic Disease
1
Prostate Adenocarcinoma
1
Newly Diagnosed Oligometastatic Prostate Cancer
1
Neoadjuvant Therapy
1
Metastatic Hormone-sensitive Prostate Cancer
1
Melanoma
1
Disease
1
Castration-resistant Prostate Cancer
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Small Cell
1
Carcinoma, Non-Small-Cell Lung
1
Anus Neoplasms
1
Interventions
enzalutamide
3
Abiraterone Acetate
2
testosterone enanthate
1
pembrolizumab
1
disitamab vedotin
1
abiraterone
1
Radium-223
1
Prednisone
1
Ketoconazole
1
Hydrocortisone
1
Flutamide
1
Calcitriol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Castration-resistant Prostate Cancer
×
abiraterone
×
Clear all
NCT02429193
2020-01-13
BARRIER-P
University Health Network, Toronto
Phase 2
Completed
16 enrolled